SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hayes-Lattin B, Nichols CR. Testicular cancer: a prototypic tumor of young adults. Semin Oncol. 2009;36:432438.
  • 2
    Einhorn LH, Williams SD. Combination chemotherapy with cis-dichlorodiammineplatinum(II) and Adriamycin for testicular cancer refractory to vinblastine plus bleomycin. Cancer Treat Rep. 1978;62:13511353.
  • 3
    Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000–2002 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784796.
  • 4
    Fossa SD, Cvancarova M, Chen L, et al. Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol. 2011;29:963970.
  • 5
    Spermon JR, Witjes JA, Kiemeney LA. Difference in stage and morphology-adjusted survival between young and elderly patients with a testicular germ cell tumor. Urology. 2002;60:889893.
  • 6
    Verhoeven RH, Gondos A, Janssen-Heijnen ML, et al. Testicular cancer in Europe and the USA: survival still rising among older patients. Ann Oncol. 2013;24:205213.
  • 7
    de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of 3 or 4 cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19:16291640.
  • 8
    Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:31873205.
  • 9
    Finkelstein DM, Muzikansky A, Schoenfeld DA. Comparing survival of a sample to that of a standard population. J Natl Cancer Inst. 2003;95:14341439.
  • 10
    Bajorin D, Katz A, Chan E, Geller N, Vogelzang N, Bosl GJ. Comparison of criteria for assigning germ cell tumor patients to “good risk” and “poor risk” studies. J Clin Oncol. 1988;6:786792.
  • 11
    Fossa SD, Oliver RT, Stenning SP, et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer. 1997;33:13801387.
  • 12
    Sant M, Aareleid T, Artioli ME, et al. Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study. Eur J Cancer. 2007;43:585592.
  • 13
    Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer. 2009;45:931991.
  • 14
    Huyghe E, Muller A, Mieusset R, et al. Impact of diagnostic delay in testis cancer: results of a large population-based study. Eur Urol. 2007;52:17101716.
  • 15
    Sekine I, Fukuda H, Kunitoh H, Saijo N. Cancer chemotherapy in the elderly. Jpn J Clin Oncol. 1998;28:463473.
  • 16
    O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2003;14:9196.
  • 17
    Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–1995: a review of patients with germ cell tumours. Br J Cancer. 1998;78:10611066.
  • 18
    Levi JA, Raghavan D, Harvey V, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma.Australasian Germ Cell Trial Group. J Clin Oncol. 1993;11:13001305.
  • 19
    Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470476.
  • 20
    de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15:18371843.
  • 21
    Toner GC, Stockler MR, Boyer MJ, et al. Comparison of 2 standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial.Australian and New Zealand Germ Cell Trial Group. Lancet. 2001;357:739745.
  • 22
    Wheater MJ, Manners J, Nolan L, Simmonds PD, Hayes MC, Mead GM. The clinical features and management of testicular germ cell tumours in patients aged 60 years and older. BJU Int. 2011;108:17941799.
  • 23
    Feldman DR, Voss MH, Jacobsen EP, et al. Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013;119:25742581.
  • 24
    Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev. 2005;31:380402.
  • 25
    Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995;1:3342.
  • 26
    Proctor SJ, Rueffer JU, Angus B, et al. Hodgkin's disease in the elderly: current status and future directions. Ann Oncol. 2002;13(suppl 1):133137.
  • 27
    Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008;111:29772983.